Energetics and Glutamate in Schizophrenia
- Disease/Condition
- Schizophrenia
- Drug/Device/Intervention
- MRI scan
- Study type
- Observational
- Intervention type
- procedure
- Primary sponsor
- King's College London
- Location
- London, United Kingdom
- Phase
- N/A
- Start date
- Mar 01, 2024
- End date
- Dec 01, 2028
- Enrollment
- 75 participants
Brain glucose utilisation,Glutamate - anterior cingulate cortex,Lactate - visual cortex,Cerebral blood flow,Cortical network activity
The goal of this case-control study is to compare brain glutamate, glucose utilisation,
 lactate production and brain activity in healthy volunteers and people with a diagnosis of
 schizophrenia.
 
 It investigates the following main questions:
 
 Whether, compared to healthy volunteers, participants with schizophrenia show:
 
 1. reduction in brain glucose utilisation
 
 2. increased brain lactate
 
 3. greater variability in brain glutamate
 
 Participants will be asked to have a screening visit, a MRI brain scan and a PET-MRI brain
 scan.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06236048
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT06236048 through Pure Global AI's free database. This phase not specified trial is sponsored by King's College London and is currently Recruiting. The study focuses on Schizophrenia. Target enrollment is 75 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.